Cite
Thirunavukarasu S, Jex N, Chowdhary A, et al. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. Diabetes. 2021;70(12):2810-2822doi: 10.2337/db21-0270.
Thirunavukarasu, S., Jex, N., Chowdhary, A., Hassan, I. U., Straw, S., Craven, T. P., Gorecka, M., Broadbent, D., Swoboda, P., Witte, K. K., Cubbon, R. M., Xue, H., Kellman, P., Greenwood, J. P., Plein, S., & Levelt, E. (2021). Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. Diabetes, 70(12), 2810-2822. https://doi.org/10.2337/db21-0270
Thirunavukarasu, Sharmaine, et al. "Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes." Diabetes vol. 70,12 (2021): 2810-2822. doi: https://doi.org/10.2337/db21-0270
Thirunavukarasu S, Jex N, Chowdhary A, Hassan IU, Straw S, Craven TP, Gorecka M, Broadbent D, Swoboda P, Witte KK, Cubbon RM, Xue H, Kellman P, Greenwood JP, Plein S, Levelt E. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. Diabetes. 2021 Dec;70(12):2810-2822. doi: 10.2337/db21-0270. Epub 2021 Oct 05. PMID: 34610982.
Copy
Download .nbib